Sadie Stern Sells 4,137 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Sadie Stern sold 4,137 shares of DexCom stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $140.00, for a total transaction of $579,180.00. Following the completion of the transaction, the executive vice president now owns 76,304 shares of the company’s stock, valued at approximately $10,682,560. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Sadie Stern also recently made the following trade(s):

• On Tuesday, March 12th, Sadie Stern sold 20,321 shares of DexCom stock. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81.
• On Tuesday, January 16th, Sadie Stern sold 2,902 shares of DexCom stock. The shares were sold at an average price of $123.63, for a total transaction of $358,774.26.

DexCom Price Performance

Shares of DXCM stock opened at $139.48 on Thursday. DexCom, Inc. has a 12-month low of $74.75 and a 12-month high of $142.00. The firm has a market capitalization of $53.77 billion, a price-to-earnings ratio of 106.47, a price-to-earnings-growth ratio of 2.41 and a beta of 1.18. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. The firm has a fifty day moving average of $125.31 and a 200-day moving average of $111.84.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. The firm had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.02 billion. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The company’s revenue was up 26.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.34 EPS. On average, equities research analysts forecast that DexCom, Inc. will post 1.76 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on DXCM shares. Royal Bank of Canada assumed coverage on shares of DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price for the company. Piper Sandler boosted their price objective on shares of DexCom from $135.00 to $150.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 19th. Wells Fargo & Company boosted their price objective on shares of DexCom from $110.00 to $136.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 13th. Morgan Stanley lifted their target price on shares of DexCom from $101.00 to $122.00 and gave the stock an “equal weight” rating in a report on Monday, December 4th. Finally, Raymond James lifted their target price on shares of DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 23rd. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $136.67.

Hedge Funds Weigh In On DexCom

A number of large investors have recently added to or reduced their stakes in DXCM. Centaurus Financial Inc. grew its holdings in shares of DexCom by 5.5% in the 1st quarter. Centaurus Financial Inc. now owns 1,236 shares of the medical device company’s stock valued at $632,000 after acquiring an additional 64 shares in the last quarter. Stableford Capital II LLC grew its holdings in shares of DexCom by 2.1% in the 4th quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after acquiring an additional 88 shares in the last quarter. Fortis Capital Advisors LLC grew its holdings in shares of DexCom by 5.5% in the 2nd quarter. Fortis Capital Advisors LLC now owns 1,744 shares of the medical device company’s stock valued at $224,000 after acquiring an additional 91 shares in the last quarter. D Orazio & Associates Inc. grew its holdings in shares of DexCom by 0.8% in the 4th quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock valued at $1,534,000 after acquiring an additional 93 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of DexCom by 10.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock valued at $133,000 after acquiring an additional 98 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.